A Phase 1, Open-Label, Single-Dose, Randomized, Three-Period Crossover Study to Evaluate the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Female Subjects of Non-Childbearing Potential
Latest Information Update: 15 Feb 2023
At a glance
- Drugs Giredestrant (Primary) ; Giredestrant (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Pharmacokinetics
- Sponsors Genentech
Most Recent Events
- 01 Feb 2023 Results assessing absorption, distribution, metabolism, and excretion of pexidartinib using radiolabeled drug from two clinical studies: NCT04037618 and NCT04274075 published in the Clinical Pharmacology in Drug Development
- 15 Apr 2020 Status changed from active, no longer recruiting to completed.
- 16 Mar 2020 Status changed from recruiting to active, no longer recruiting.